- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Duisburg, Essen, Universität Duisburg-Essen, Dissertation, 2019
- Schlagwort
-
Cancer
Expression
- Ereignis
-
Veröffentlichung
- (wo)
-
Duisburg, Essen
- (wer)
-
Universität Duisburg-Essen
- (wann)
-
2019
- Urheber
- Beteiligte Personen und Organisationen
-
Führer-Sakel, Dagmar
- DOI
-
10.17185/duepublico/70705
- URN
-
urn:nbn:de:hbz:464-20191120-110257-3
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zeng, Xiangtai
- Führer-Sakel, Dagmar
- Universität Duisburg-Essen
Entstanden
- 2019
Ähnliche Objekte (12)
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD‐L1 and CTLA‐4
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?